Dr Elias Björnson, University of Gothenburg, Sweden
In the 12 months since Lp(a) Forum was launched in April 2024, we have seen some remarkable progress in the field of Lp(a) research. As scientists, we now understand a lot more about the atherogenicity of Lp(a) particles, and the specific lipid components, such as diacylglycerols (DG) and lysophosphatidic acid (LPA), that contribute to their atherogenicity.
Clinically, there has been growing recognition of the importance of Lp(a) screening in routine patient care and, of course, we have seen some very encouraging clinical trial results for novel Lp(a) targeted drugs.
